Loading...
Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Loading...
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Cephalotaxus harringtonia
Conifère japonais et chinois contenant l'homoharringtonine, utilisé pour développer l'omacetaxine contre la leucémie myéloïde chronique.
Cephalotaxus harringtonia is a coniferous tree native to East Asia, whose alkaloids—particularly homoharringtonine—have been developed into the pharmaceutical agent omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML). The plant also contains harringtonine and cephalotaxine, which contribute to its traditional use as an antitumor and anti-inflammatory remedy. Modern research focuses on its alkaloid content for anticancer applications, though clinical use is limited to purified omacetaxine due to toxicity.
Homoharringtonine (omacetaxine) inhibits protein synthesis by binding to the A-site of the 60S ribosomal subunit, preventing aminoacyl-tRNA binding and peptide chain elongation. This action preferentially suppresses the translation of short-lived proteins, including the BCR-ABL oncoprotein in CML cells, leading to apoptosis. Additionally, harringtonine and cephalotaxine may modulate topoisomerase activity and induce cell cycle arrest, though these effects are less characterized. The alkaloids also exhibit anti-inflammatory activity via inhibition of NF-κB signaling and reduction of pro-inflammatory cytokines.
Conifère japonais et chinois contenant l'homoharringtonine, utilisé pour développer l'omacetaxine contre la leucémie myéloïde chronique.
Cephalotaxus harringtonia is a coniferous tree native to East Asia, whose alkaloids—particularly homoharringtonine—have been developed into the pharmaceutical agent omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML). The plant also contains harringtonine and cephalotaxine, which contribute to its traditional use as an antitumor and anti-inflammatory remedy. Modern research focuses on its alkaloid content for anticancer applications, though clinical use is limited to purified omacetaxine due to toxicity.
Homoharringtonine (omacetaxine) inhibits protein synthesis by binding to the A-site of the 60S ribosomal subunit, preventing aminoacyl-tRNA binding and peptide chain elongation. This action preferentially suppresses the translation of short-lived proteins, including the BCR-ABL oncoprotein in CML cells, leading to apoptosis. Additionally, harringtonine and cephalotaxine may modulate topoisomerase activity and induce cell cycle arrest, though these effects are less characterized. The alkaloids also exhibit anti-inflammatory activity via inhibition of NF-κB signaling and reduction of pro-inflammatory cytokines.